Aurobindo pharma ltd generic licensing

2,260 views

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
2,260
On SlideShare
0
From Embeds
0
Number of Embeds
16
Actions
Shares
0
Downloads
50
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Aurobindo pharma ltd generic licensing

  1. 2. AUROBINDO PHARMA LTD. <ul><li>Aurobindo is a Young Indian Pharmaceutical company born in Year 1986. </li></ul><ul><li>Aurobindo's mission is to become the most valued Pharma partner for the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products complying to the highest regulatory standards. </li></ul><ul><li>A well integrated pharma company with focus on formulations. </li></ul><ul><li>Vertically Integrated pharmaceutical company with huge capacity giving economies of scale. </li></ul><ul><li>In house R&D for rapid filing of Patents, ANDAs & DMFs </li></ul><ul><li>Global Regulatory approved manufacturing base </li></ul><ul><li>Global presence with manufacturing infrastructure, strategic alliances, subsidiaries and joint ventures. </li></ul><ul><li>Exporting to 125+ countries with 70%+ of revenues from international operations </li></ul><ul><li>Well spread global marketing network through 40 subsidiaries </li></ul><ul><li>Employee base of 7800+ including 700+ scientists </li></ul><ul><li>Strong foundation for sustained organic growth </li></ul>
  2. 3. AUROBINDO PHARMA LTD. <ul><li>INFRASTRUCTURE </li></ul><ul><ul><li>Over 5 million sq meter area spread for state of the art manufacturing facilities. </li></ul></ul><ul><ul><li>Facilities approved by USFDA, UK-MHRA, FEMIA,INFARMED, PT, MCC South Africa, Anvisa-Brazil and many other regulated and semi-regulated drug Minsitry. </li></ul></ul><ul><li>R&D </li></ul><ul><ul><li>Aurobindo's R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenge </li></ul></ul><ul><li>Product Portfolio </li></ul><ul><ul><li>Therapeutic Segments comprise of Antibiotics, ARVs, CNS, Anti Depressants, Anti Alzheimer, Gastroenterological. </li></ul></ul><ul><ul><li>Over 250 formulations including immediate release, control release, mouth disintegration tablets, capsules, liquids and Lyophilized Sterile Inj. </li></ul></ul><ul><ul><li>Huge Product Portfolio of EU CTD Dossiers for Out-Licensing Operations. </li></ul></ul><ul><li>Marketing </li></ul><ul><ul><li>Global Marketing Infrastructure through subsidiaries, distribution, joint ventures. </li></ul></ul><ul><ul><li>Exports to over 100 countries with significant strategic marketing presence in USA, Europe, Latin America, CIS, SEAN. </li></ul></ul><ul><ul><li>Subsidiaries across the Globe. </li></ul></ul><ul><li>Milestone </li></ul><ul><ul><li>Year 2010-11 : The company is in its celebration of Silver Jubilee Year of Operations and CROSSED BILLION DOLLARS mark of consolidated total operating income. </li></ul></ul><ul><ul><li>57.3% - Formulation Business (Up By 30% from the previous Year) </li></ul></ul><ul><ul><li>64% Business from International Operations. </li></ul></ul><ul><ul><li>227 Dossier Filings in Europe (Year 2010-11), cumulative filings 991 </li></ul></ul><ul><ul><li>Amongst top 5 Pharma companies in India interms of exports and revenue. </li></ul></ul>

×